A Phase I, Open Label, Multicenter Study to Assess the Safety, Tolerability and Pharmacology of AZD2281 in Combination With Liposomal Doxorubicin (Caelyx) in Patients With Advanced Solid Tumors
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 03 Apr 2018
At a glance
- Drugs Olaparib (Primary) ; Doxorubicin liposomal
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors AstraZeneca
- 28 Mar 2018 Planned End Date changed from 31 Dec 2017 to 31 Dec 2018.
- 18 Sep 2017 Planned End Date changed from 30 Sep 2017 to 31 Dec 2017.
- 05 Sep 2017 Planned End Date changed from 31 Aug 2017 to 30 Sep 2017.